Pharma News

The European Union has introduced significant updates to its Health Technology Assessment (HTA) regulations, aiming to accelerate drug access for patients across member states.

On February 11, Novartis announced its first acquisition of the year, acquiring Anthos Therapeutics for an upfront payment of $925 million and an additional $2.15 billion in milestone payments.

This combination therapy is the first to demonstrate a significant OS benefit for mCRPC patients in a randomized controlled trial, regardless of whether patients carry homologous recombination repair (HRR) gene mutations.

As of February 13, a total of 257 biopharmaceutical companies have disclosed their performance forecasts for 2024, with over 50 firms expecting to see their net profits double.

Union Health Ministry has granted a conditional extension for small and medium drug manufacturers to comply with the revised Schedule M norms, now set to be implemented by December 31, 2025.

Ozempic, the popular GLP-1 diabetes medication from Novo Nordisk, has demonstrated encouraging results in a recent study addressing alcohol use disorder.

AstraZeneca India has announced plans to sell its 64-acre production facility in North Bengaluru for Rs 3,200 crore as part of a broader strategic review of its global manufacturing and supply chain.

Nucleus Gene and its legal representative Zhang Hezi have become restricted consumers due to a failure to comply with court orders, linked to an execution amount of 200,000 yuan.

On January 5, Poly Pharm announced that it is under investigation by the China Securities Regulatory Commission (CSRC) for suspected violations of information disclosure laws.

Vertex Pharmaceuticals is making headlines with the upcoming launches of three pivotal products: the sickle cell disease gene therapy Casgevy, the company’s fifth cystic fibrosis treatment Alyftrek, and the newly approved non-opioid pain relief medication

Merck KGaA (MRCG.DE), the German healthcare and technology powerhouse, announced on Monday that it is in advanced negotiations to acquire U.S. biotech firm SpringWorks Therapeutics (SWTX.O), known for its focus on cancer and rare diseases.

Eisai is doubling down on its Alzheimer’s disease antibody, Leqembi, which is showing signs of significant growth potential nearly two years post-launch.

This winter has felt exceptionally long for the pharmaceutical industry. Since the summer of 2021, few anticipated that the downturn would extend beyond three and a half years, leading even the most patient investors to the brink of despair.

According to a review by Cybex, AstraZeneca emerged as the clear leader with $6.41 billion in revenue, reflecting an impressive 11% growth.

Novartis has announced that its nuclear medicine product, Pluvicto (177Lu-PSMA-617), achieved $1.39 billion in sales for the year 2024, marking a 42% increase compared to the previous year.

The pharmaceutical industry is experiencing a significant wave of layoffs, with reports indicating that the number of job cuts at major companies has soared to 42 rounds in 2024, reflecting an astonishing 282% increase.

Pfizer disclosed a $2 billion impairment on its intangible assets, specifically related to Vadistuzumab (an anti-HER2 ADC) acquired from Rongchang Biopharma.

The global pharmaceutical landscape has dramatically shifted as 2025 approaches, marking a significant reshuffle among the top players.

On February 6, AstraZeneca announced it has received a notification from Chinese authorities regarding $900,000 in unpaid import taxes related to two of its cancer medications.

Amgen announced the suspension of its weight loss drug AMG 133 (MarTide), a decision that has garnered significant attention.